We are live on ! Find out more
BSPM

Biostar Pharmaceuticals, Inc.
BSPM

Delisted

BSPM was delisted on the 18th of September, 2018.

Back to rankings

6 hedge funds and large institutions have $203K invested in Biostar Pharmaceuticals, Inc. in 2016 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% less funds holding

Funds holding: 8 → 6 (-2)

37% less capital invested

Capital invested by funds: $324K → $203K (-$121K)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
6
Holders Change
-2
Holders Change %
-25%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$8.64K
2
UBS Group
UBS Group
Switzerland
+$2.13K
3
TRCT
Tower Research Capital (TRC)
New York
+$1.7K
4
Deutsche Bank
Deutsche Bank
Germany
+$2

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$21K
2
VKH
Virtu KCG Holdings
New York
-$8K
3
California Public Employees Retirement System
California Public Employees Retirement System
California
-$6K
4
ISB
Iowa State Bank
Iowa
-$5K

BSPM Hedge Fund Activity: Q1 2016 in Review

6 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Biostar Pharmaceuticals, Inc. (BSPM) for Q1 2016, worth a combined $203K — down 37% from $324K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of BSPM and 2 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 2 added.

The largest buyer was Renaissance Technologies, adding an estimated $8.64K. The largest seller was Citadel Advisors, exiting entirely with an estimated $21K sold.

  • 6 institutional investors held Biostar Pharmaceuticals, Inc. (BSPM) as of Q1 2016, down from 8 in Q4 2015.
  • Funds reported $203K of Biostar Pharmaceuticals, Inc. stock for Q1 2016, down 37% quarter-over-quarter.
  • 2 funds opened new Biostar Pharmaceuticals, Inc. positions in Q1 2016 and 4 closed out, a net change of -2 holders.
  • The largest Biostar Pharmaceuticals, Inc. buyer in Q1 2016 was Renaissance Technologies, an estimated $8.64K added.
  • The largest Biostar Pharmaceuticals, Inc. seller in Q1 2016 was Citadel Advisors, an estimated $21K sold.

Based on aggregated 13F filings for Q1 2016.